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1. Introduction
Polyelectrolytes consist of long linear or branched macro-
molecules that contain charged units. When dispersed in
water or a sufficiently polar solvent, the counterions balanc-
ing the charge of the polyelectrolyte will partially dissociate.
Therefore, the properties of polyelectrolytes in solution will
be greatly determined by their counterions. Polyelectrolytes
are ubiquitous in biological systems and play a central role in
almost all biochemical processes.[1] DNA is perhaps the best-
studied natural polyelectrolyte and in the preceding 50 years
most work has been directed towards a detailed understand-
ing of the interaction between DNA and proteins related to
DNA repair proteins or transcription factors.[2–11] The ther-
modynamics of the binding of DNA or RNA to proteins has
been shown to be dominated by charge–charge interactions,
and the biological activity of natural polyelectrolytes such as
DNA is intimately related to their highly charged molecular
structures.[2, 12–15] Heparin provides another example of a nat-
ural polyelectrolyte with four charges per repeating unit that
has been studied intensively during the last 30 years.[16–19]
Synthetic polyelectrolytes, on the other hand, have
become valuable tools for various medical purposes during
the past 20 years. Thus, complexes of synthetic polyelectro-
lytes with DNA are now used as nonviral vectors for gene
delivery.[20, 21] Research along this line has been aimed at well-
defined complexes with optimized efficiency. More recently,
block copolymers containing cationic sequences have been
used for this purpose, and transfection using polycations is an
active field of polymer science these days.[22–25] Other polymer
architectures used so far include nanogels,[26–29] which consist
of crosslinked polyelectrolytes.[30, 31] These systems have also
become another highly useful device for gene deliv-
ery[21, 25, 26, 32,33] as well as for the defined uptake and delivery
of proteins and drugs in general.[23, 25]
An equally fascinating and rather recent development is
the use of polyelectrolytes as drugs themselves.[34] Here,
sulfated dendritic polyglycerol sulfate
(dPGS), which consists of a dendritic
poly(glycerol) scaffold with each sul-
fated end group bearing a negative charge, has become
a focus of our research.[35] First designed as a replacement for
heparin,[34] dPGS has been used for a variety of biomedical
purposes that range from tumor targeting to anti-inflamma-
tory treatment.[34,36] Previous studies suggest that the inter-
action of dPGS with various proteins and cell-surface
molecules proceeds in a specific way. Thus, Dernedde
et al.[36] surmised that dPGS can block the cell adhesion
molecules (CAMs) L- and P-selectin on leukocytes and
activated endothelial cells, respectively, which are central to
The counterions neutralizing the charges on polyelectrolytes such as
DNA or heparin may dissociate in water and greatly influence the
interaction of such polyelectrolytes with biomolecules, particularly
proteins. In this Review we give an overview of studies on the inter-
action of proteins with polyelectrolytes and how this knowledge can be
used for medical applications. Counterion release was identified as the
main driving force for the binding of proteins to polyelectrolytes:
Patches of positive charge become multivalent counterions of the
polyelectrolyte and lead to the release of counterions from the poly-
electrolyte and a concomitant increase in entropy. This is shown from
investigations on the interaction of proteins with natural and synthetic
polyelectrolytes. Special emphasis is paid to sulfated dendritic poly-
glycerols (dPGS). The Review demonstrates that we are moving to
a better understanding of charge–charge interactions in systems of
biological relevance. Research along these lines will aid and promote
the design of synthetic polyelectrolytes for medical applications.
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inflammatory processes, through a selective charge–charge
interaction. Hence, dPGS seems to act as a macromolecular
inhibitor that may mimic naturally occurring ligands.
Prompted by the success of dPGS as an anti-inflammatory
compound, a number of structures have been synthesized that
contain dPGS as a building block for various biological
processes in which inflammation plays a central role: Nano-
gels based on dPGS with different degrees of flexibility have
been shown to possess antiviral properties.[37] dPGS has also
been used as a building block for micellar structures that can
be used for targeting tumor cells.[38] Furthermore, its inter-
action with neural microglia has been the subject of several
studies.[39, 40] Substituted polyglycerols bearing positive
charges have been introduced as potent antibleeding agents
with excellent anticoagulant reversal activity upon binding
the polyanion heparin.[41–43]
Summing up all the research done to date, it is fair to state
that a large number of charged polymeric systems and
potential drugs have been synthesized recently and the
possible medical applications of these systems are hard
to overlook.[23, 25] However, only a small subset of polyelec-
trolyte systems has reached the stage of clinical trials. The
problems at hand are: Such polymeric drugs must remain
active in the complex environment of cells or a multitude of
proteins in the blood stream. Ideally, the drug should interact
only with a chosen target structure in a highly specific
manner. Unspecific interaction with blood proteins should be
avoided. At this moment, we clearly lack a general under-
standing of these systems, which would allow us to design
them in a straightforward manner to circumvent these
problems.
To make progress in this field we need a quantitative
understanding of the interaction of polyelectrolytes with
proteins in general. In this Review we discuss recent work
along these lines and how the analysis and the modeling of the
interaction of polyelectrolytes with proteins can be used for
a rational design of charged polymeric drugs. The central
hypothesis of the present discussion is that this interaction is
largely dominated by counterion release. Figure 1 shows this
process in a schematic fashion: We consider the interaction of
a protein carrying surface charges with a highly charged linear
polyelectrolyte. A fraction of the counterions around the
polyelectrolyte is “condensed”, that is, closely bound to the
macroion.[1] Proteins, in general, are polyampholytes, which
carry patches of negative and positive charge on their surface.
Most proteins bear an overall negative charge under physio-
logical conditions. However, the patches bearing a positive
charge remain and can interact with negatively charged
polyelectrolytes such as DNA or heparin. In this way, the
proteins become multivalent counterions of the polyelectro-
lyte, thereby releasing a concomitant number of its mono-
valent counterions. The gain in entropy thus achieved is the
main driving force.[2] Detailed considerations to be discussed
further below demonstrate that this counterion release force
is operative even under a physiological salt concentration of
150 mm.
Inspired by earlier work on the interaction of DNA with
various proteins,[2,10, 13, 14,46–49] we recently reconsidered the
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problem of counterion release by a series of thermodynamic
studies related to the interaction of polyelectrolytes with
proteins. First, the interaction of human serum albumin
(HAS) with short-chain poly(acrylic acid) in aqueous solution
was studied by a combination of calorimetry and molecular
dynamics simulations.[50] We also studied the binding of dPGS
of different generations[51] to lysozyme[45, 52] and to HSA.[53]
Recently, this work has been continued to include a quanti-
tative discussion of the role of water in the binding process.[54]
In addition to this, we demonstrated that MD simulations can
reproduce the experimental binding constant of L-selectin to
second-generation dPGS with surprising accuracy and be
rationalized in terms of counterion release.[45] The latter result
could hence furnish a quantitative proof of earlier conjec-
tures[36] on the use of dPGS as an anti-inflammatory drug. In
this way we have acquired a rather advanced understanding of
the interaction of dPGS with various systems of medical
relevance.
Here we survey this work and how it can be applied for
a better understanding and design of polyelectrolytes for
medical purposes. Special emphasis will be laid on biomedical
applications of dPGS and related systems. It is organized in
terms of the matrix of chemical systems and biochemical
problems with increasing complexity shown in Figure 2.
Hence, the Review is subdivided in three parts as follows:
1. In the next section, we shall discuss the current under-
standing of the interaction of proteins with linear poly-
electrolytes.[2, 10, 11, 45,49, 52, 53] This section will survey the
formation of complexes of proteins with DNA, which
presents the best-studied case in this field. At a higher
level of biological complexity, problems related to drug
delivery,[32, 60, 61] gene transfection, und ultimately gene
therapy will be discussed. Glycosaminoglycans (GAGs)
such as heparin or heparan sulfate, which consist of
disaccharide units that may be sulfated, present another
important class of natural, highly charged polyelectro-
lytes.[18,19, 62] GAGs are important components of the
extracellular matrix of cells. It has been recognized for
a long time that the interaction with proteins is driven by
electrostatic forces and counterion release.[63–65] This fact is
underscored by more recent studies[66–68] and will be
discussed as well.
2. The next level of complexity is given by dendritic and
hyperbranched polyelectrolytes, charged networks, and
polyelectrolyte brushes. Here, collective effects caused by
the polymer architecture and their consequences for the
interaction with proteins will be discussed. In particular,
the counterion dPGS belongs in this section, which also
contains the consequences for virus binding[69] and inacti-
vation as well as for the diagnostics and therapeutic use of
dPGS in anti-inflammation.[36, 70] This section will also
highlight the interaction of proteins with polyelectrolytes
of higher complexity, such as charged net-
works.[21,27, 31, 32, 37,56, 71] This work can be rationalized with
recent theoretical studies on these systems.[72–76] The
interactions of charged polyglycerols with cellular systems
will also be discussed at this point.[36, 77–81]
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3. Finally, a section devoted to complex polyelectrolyte
architectures will highlight polyelectrolyte systems with
higher complexity, such as micelles and designed poly-
meric structures that act as anticoagulants.[25, 38] These
systems are far more difficult to understand in a quantita-
tive fashion. However, there has been some progress
towards medical applications recently, which will be
discussed here. Thus, micelles coated by a layer of dPGS
have been used as a drug in tumor targeting.[38] Moreover,
there have been recent successful developments of cat-
ionic polyelectrolyte drugs with heparin-reversal activity
in blood.[41, 42]
The entire discussion will highlight the general impor-
tance of electrostatic factors for the self-assembly and
biological activity of charged polymeric systems. As shown
in Section 2, the driving forces are now rather well under-
stood. Hence, this knowledge can now be used for the rational
design and modeling of more complicated systems, as
discussed in Sections 3 and 4. Steps in this direction will be
discussed for all systems considered in Figure 2.
2. Fundamentals and Linear Polyelectrolytes
2.1. Theory
Up to now, the interaction of linear polyelectrolytes with
proteins has been considered for two classes of problems,
namely, the 1) interaction of natural polyelectrolytes (mainly
DNA) with various proteins, and 2) interaction of synthetic
polyelectrolytes with proteins. There is great number of
studies devoted to the latter systems, since the classical
investigations of Bungenberg de Jong in the 1930s (cf. the
review of this work in Refs. [82,83]). However, in many cases,
mixing of synthetic polyelectrolytes with various proteins
leads to phase separation (complex coacervates), which
constitutes a problem of its own,[82,84–87] and which may lead
to a complex phase behavior.[88,89] DNA, on the other hand,
forms well-defined 1:1 complexes with proteins, such as
polymerases,[7,90–94] that can be understood in terms of
a chemical equilibrium. This fact was recognized a long time
ago[2, 12] and counterion release has been singled out as the
main driving force for binding. The basic argument can be
understood as follows: As depicted in Figure 1, there is
a certain fraction of counterions that are condensed to the
linear polyelectrolyte. The fraction of condensed counterions
can be estimated from a relationship described by Man-
ning:[12,95] If b is the distance between two charges along the





Here, lB is the Bjerrum length (lB ¼ kBT4pee0; e : dielectric
constant of the medium, kB : Boltzmann constant, e0 : permit-
tivity of the vacuum, T: absolute temperature). If x> 1,
a fraction 11/x of the counterions will be condensed onto the
linear chain, that is, strongly correlated with the polyelectro-
lyte. It is important to note that this fraction does not
contribute to the osmotic pressure of the system. For DNA,
this fraction amounts to about 70% of all counterions. The
condensed counterions can be regarded as a phase that may
be characterized by a “surface concentration” cci, which for
DNA is of the order of 1m.[12]
If we consider the interaction of such a highly charged
polyelectrolyte with a protein, these condensed counterions
must be treated as a reaction partner and, thus, contribute to
the stoichiometry of the reaction.[2, 12] Hence, the complex-
ation of a protein P with an anionic polyelectrolyte PE to
a complex PEP is defined by Equation (2).[2]
Pþ PEÐ PEPþ DnciMþ ð2Þ
Here, Dnci denotes the number of cations of type M
+ that
have been released during the course of the binding reaction.
The measured equilibrium constant Kb can be formulated in
Figure 1. Interaction of proteins with highly charged polyelectrolytes,
for example, DNA, by counterion release: Proteins bear negative (red)
and positive charges (blue) on their surface. Above the isoelectric
point, the overall surface charge is negative, but the positive patches
remain. The polyelectrolyte bears a large number of charges that will
lead to counterion condensation, that is, a certain fraction of the
counterions are highly correlated with the polyelectrolyte, as shown
here. Upon binding of the protein to the polyelectrolyte, a positive
patch on the surface of the protein becomes a trivalent counterion of
the polyelectrolyte. Thus, three counterions condensed on the polyelec-
trolyte are released upon binding. The free energy of binding will,
therefore, be dominated by the entropic gain through the release of
the counterions.[12, 44, 45] For the sake of clarity, only the condensed
counterions are shown here. However, all the charges on the protein
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terms of molar concentrations, and its relationship to the
thermodynamic constant KT related to the activities of the
components is given by Equation (3).[2]
lnKb ¼ lnKT þ ln
gPgPE
gPEP
DncilngM  Dnciln½Mþ ð3Þ
Here, gP, gPE, gPEP, and gM denote the activity coefficients
of the protein, the polyelectrolyte, the complex, and the free
ions, respectively (see also the discussion of this problem in
Ref. [54]). Since the concentration [M+] of monovalent
cations is much larger than the concentrations of the
polyelectrolyte and the protein, [M+] equals, to an excellent
approximation, the concentration of added salt cs. First, the
activity coefficient of the ions can be disregarded, since we
deal mostly with small concentrations of the ions. Moreover, it
can be shown that the second term on the right-hand side of
Equation (3) related to the activity coefficients give a small
but non-negligible contribution for linear polyelectrolytes
that scales with ln(cs).
[44, 96] This term contains the Debye–
Hckel interactions of the various parts of the complex. For
complexes of proteins with spherical polyelectrolytes, all
contributions from activity coefficients may be shown to be
small and negligible to a first approximation.[54] Hence, to
a good approximation, Equation (3) can be simplified to
Equation (3a).
lnKb  lnKb 1Mð Þ Dncilncs ð3aÞ
Here, Kb(1m) is the binding constant extrapolated to one
molar salt concentration. Thus, the stoichiometric coefficient
Dnci is given to a good approximation bydlnKb=dlncs, that is,
by the negative slope of the plots of the log of the measured
equilibrium constant Kb against log cs. Only at very low ion
concentrations of the order of 1 mm and less will the data
deviate from linearity because of a non-negligible repulsive
Debye–Hckel interaction.[54,97]
Many years ago, Tanford argued that Equation (3) needs
to be supplemented by a term that takes into account the
number Dw of released or bound water molecules during the
course of complex formation.[98] Thus, a term scaling such as
(ni/nw)Dw should be included in Equation (3). Here, ni and
nw denote the molar number of ions and of water molecules in
the system, respectively. However, ni is typically of the order
of 102 to 101, whereas nw is 55.6. Hence, this term, which
reflects the change of hydration during complex formation, is
small and can be dismissed for low ion concentrations ni.
[2,98]
This term comes into play for high ion concentrations in
excess of 1m.[99–101] In this case, plots of logKb versus logcs are
no longer linear. This problem has been studied in a series of
Figure 2. Interaction of polyelectrolytes with biosystems at different levels of complexity: Linear polyelectrolytes may be assembled into
networks[55, 56] and branched systems. Ultimately, they may become building blocks for systems with higher complexity, for example, micelles with
core–shell structures. Complexity on the biological side starts with single protein molecules that can interact with polyelectrolyte systems with
various architectures. On this level, the therapeutic activity of polyelectrolytes can often be traced back to a blocking of proteins by a suitable
polyelectrolyte system.[31, 36, 39, 40, 42, 45] Cells present the next level of complexity and their interaction with charged polymeric systems must be
understood when considering these systems for, for example, drug delivery or gene transfection.[20, 22, 57, 58, 59] Organs present the highest level of
complexity and the understanding of their interaction with synthetic polyelectrolyte systems is in its infancy. However, cationic polyelectrolytes
with suitable architectures have recently been introduced as agents with anticoagulant reversal activity in blood.[41–43] The entire matrix of systems
and problems gives a good overview of the possible medical problems to which synthetic polyelectrolytes may provide solutions.
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important investigations by Bergqvist, Ladbury, and co-
workers.[99, 100,102, 103] Here, plots according to Equation (3)
indeed exhibit a marked curvature, which can be explained in
terms of a model taking into account the release of water
molecules during binding.[98,104, 105] A much-refined discussion
of the release of water was presented by Record and co-
workers,[106, 107] who demonstrated that Dw is intimately
related to the preferential adsorption of the ions on the
surface of the biomolecule (cf. Ref. [106] and further refer-
ences therein). The model of vander Meulen et al.[107] predicts
that Dw vanishes if there is no preferential adsorption of the
co- or counterions. The analysis of experimental data on the
binding of proteins to DNA led vander Meulen et al. to the
conclusion that Dw is small if salts in the middle of the
Hofmeister series,[108] for example, NaCl or KCl, are used.
Hence, Dw will be small, and nearly all complexes of
DNA with proteins have been modeled by Equa-
tion (3a).[2, 10, 13, 14,46–49]
Equation (3a) can be used to analyze the measured binding
constant Kb further by splitting it up through extrapolation to
a 1m salt concentration. Thus, Kb now consists of a reference
part Kb(1m) and a term depending solely on the release of
counterions.[10, 11] Equation (4) gives Equation (5), where
DGres is the residual of the Gibbs free energy of binding
derived from Kb(1m), whereas DGci denotes the part related
to counterion release.[11]
DGb ¼ RTln Kb ð4Þ
DGb ¼ DGres þ DGci ð5Þ
Extrapolation of the measured Kb value to a 1m salt
concentration according to Equation (5) leads to DGres, that is,
DGres =RTln(Kb(1m)), and in turn to DGci. Here, the
quantity DGres denotes all contributions to the free energy
of binding which are not from counterion release, such as
direct electrostatic interaction,[54] hydrogen bonding, or salt
bridges as well as other effects. In this way, the salt
concentration of 1m constitutes a reference state.
From the above approximations, counterion release is
a fully entropic effect and we obtain Equation (6).[54]




Here, DSci denotes change in entropy of the counterions,
which can be calculated from the surface concentration cci
introduced above.[45, 52,109–111] The quantity cci can be estimated
for linear polyelectrolytes from x as prescribed by Manning[12]
or it can be deduced from molecular dynamics simulations, as
shown recently.[45] Moreover, with the total binding entropy
DSb being known, the residual part DSres can be calculated
with Equation (7).[11, 54]
DSresðTÞ ¼ DSbðTÞDSci ð7Þ
It is evident from Equations (1)–(7) that a comprehensive
thermodynamic analysis of the binding of proteins to
polyelectrolytes can be achieved.
We now turn to an important tool that has been pivotal for
thermodynamic analysis: In the last two decades isothermal
titration calorimetry (ITC) has become the central tool for the
analysis of complex formation in natural and synthetic
systems.[112, 113] ITC measures directly the heat evolved upon
complex formation with high precision. Thus, by using ITC,
the Kb value of DNA with a great variety of proteins can be
determined with high accuracy;[112, 114, 115] a large number of
such studies have now been carried out.[13, 47, 90, 91,116–123] It is fair
to state that most of the quantitative knowledge on the
interaction of polyelectrolytes with proteins has been
acquired by ITC experiments and this method holds great
promise for further understanding of these systems, in
particular when applied to the design of pharmaceutical
systems.[112, 124]
2.2. Enthalpy–Entropy Compensation
Investigations by ITC and application of Equation (4)
have led to a great amount of precise thermodynamic data.
Here, studies of the dependence of the binding constant Kb on
temperature revealed a strong enthalpy–entropy compensa-
tion, that is, most of the measured binding enthalpy is
balanced by a concomitant entropic contribution. This
enthalpy–entropy compensation (EEC)[13,49, 125–128] has been
a controversial subject for quite some time.[129–132] However,
Grunwald and Steel[133] pointed out many years ago that the
EEC is the natural consequence of the rearrangement of
solvent molecules around a solute. This idea was reviewed
carefully more recently by Liu and Guo.[134] Moreover, Li
et al. showed that the EEC is a real effect with a sound
experimental basis.[135] This is in full agreement with recent
experimental studies of the Whitesides group that explain the
EEC by the reformation of the water network around the
complex.[132] Jen-Jacobson and co-workers showed that EEC
exists in systems of biological relevance.[13, 14, 49, 136] Synthetic
systems have been studied with equal intensity,[134] and from
the vast amount of literature we only cite the very recent
investigation by Schçnbeck and Holm[137] on the EEC for
complexes of cyclodextrin with various host molecules.
Dragan et al. have recently suggested that EEC may be
related to the release or uptake of water.[11] In Section 3 we
will discuss our recent studies on the EEC for the interaction
of dPGS with various proteins, which come to the same
conclusions.[52–54] Summing up this survey of theoretical and
experimental work that now extends over 50 years,[125] it is
clear that EEC is a ubiquitous phenomenon that has been
firmly established by a great number of experimental studies.
2.3. Interaction of DNA with Proteins
In this section, the above conclusion will be compared
with experimental findings. Here we start with a survey on
studies carried out on natural systems. For a long time[2] the
interaction of DNA with various proteins has been analyzed
in terms of Equation (3). The application of Equation (3a) to
the formation of protein/DNA complexes has been analyzed
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for a wide variety of systems by Privalov, Dragan, and Crane-
Robinson.[10] In all cases, straight lines were obtained indeed
by application of Equation (3a). Moreover, the number of
released ions Dnci is found to be strictly correlated to the
number of ionic contacts seen between DNA and the protein
in crystal structures (cf. the discussion in Ref. [10]). It should
be noted that ion-specific effects may change Dnci slightly and
should be considered carefully.[10] Furthermore, the binding of
DNA to proteins may lead to changes of the secondary
structure and the partial refolding of proteins. This point has
been discussed in detail by Privalov et al.[10, 138] and by Jen-
Jacobson et al.[13, 49]
Dragan et al.[11] have used Equation (5) to split the
measured DGb into the part corresponding to counterion
release and a residual part. A similar analysis has been
applied to the binding of DNA to proteins by other research
groups as well. In particular, Dragan et al. could demonstrate
that the EEC is an entirely non-electrostatic phenomenon:
Plotting the measured binding enthalpy DHb against the
residual entropy DSres resulted in a perfect master curve
[11] for
some 30 DNA/protein complexes. The authors concluded that
the EEC observed in these systems must, hence, be due to
hydration, that is, the release or uptake of water. The same
master curve was found by us for the system dPGS/
lysozyme,[54] which will be discussed further in Section 3.
2.4. Interaction of RNA with Proteins
There are much fewer thermodynamic studies on the
interaction of RNA with various proteins that consider
explicitly the dependence on ionic strength in terms of
Equation (3). Maiti and co-workers presented a comprehen-
sive study of the interaction of HIV-1 TAR RNA and Tat-
derived arginine-rich peptides by various techniques, includ-
ing ITC.[139] Plots of the binding constant according to
Equation (3a) are linear and show that one ion is released
upon binding. Samatanga et al. investigated the interaction of
single-stranded RNA with various proteins containing various
RNA-recognition motifs by ITC.[140] Use of Equation (3a)
demonstrated that the ionic interaction is small for these
systems and DGres is mainly dominated by hydrogen bonding.
It is interesting that both studies found the interaction of
RNA with the respective proteins to be mainly driving by
enthalpy. Cababie et al. recently presented a carefully con-
ducted thermodynamic study of the interaction of the NS3
helicase with single-stranded RNA by using fluorescence
titration.[141] Equation (3a) was shown to give a good descrip-
tion of the measured binding constants. Typically, Dnci was
found to be five and rather independent of the ions used for
adjusting cs.
2.5. Glycosaminoglycans (GAG) as Highly Charged
Polyelectrolytes
Glycosaminoglycans (GAGs) such as heparin consist of
oligosaccharide units that may be sulfated.[16,18, 19] Animal
tissues contain multiple sulfated glycosaminoglycans, such as
heparan sulfate (HS), heparin, chondroitin sulfate (CS),
dermatan sulfate (DS), and keratan sulfate (KS), which can
be distinguished by their sugar constituents and sulfation
pattern.[19] Figure 3 displays the repeating unit of heparin,
which is the most-studied GAG. In general, GAGs exhibit
variations of the molecular structure, and the degree of
sulfation may change. Thus, Figure 3 shows only the most
abundant repeating unit (see the discussion of this point in
Ref. [19]). Heparin has four charges per disaccharide repeat
unit and is one of the most highly charged biopolymers.
Heparin acts as an anticoagulant[42] and can interact with
various proteins.[17,62, 142, 143] Moreover, hydrogels consisting of
heparin and modified GAG units are capable of sequestering
proteins and, in particular, cytokines that may prevent wound
healing.[30, 56,144] Heparan sulfate (HS), which is slightly less
sulfated than heparin, is located in the extracellular matrix
and serves as a primary receptor for many pathogens, such as
bacteria and viruses. HS was shown to be involved in the
infection by many viruses through facilitating their internal-
ization or interaction with secondary receptors.[37, 69, 79, 80,145]
Thus, it is now clear that attachment of many viruses to
cells involves electrostatic interactions with HS.[145] Therefore,
a number of sulfated molecules have been investigated as
inhibitors (cf. the discussion of Table 2 in Ref. [145]). In
general, GAGs have been tested for sequestering or the
defined delivery of cytokines and growth factors.[19] A
thorough and quantitative understanding of the interaction
of GAGs with proteins is a central problem in biomedical
research.
Since the early work of Olson et al.[63] and of Mascotti and
Lohman[64] it is well-established that electrostatic interaction
and counterion release play a central role in the binding of
proteins to heparin.[83, 146–152] The prevalence of electrostatic
interactions beween proteins and heparin has been corrobo-
rated by a considerable number of investigations;[68,83, 151, 153,154]
a survey of the older literature may be found in the review by
Seyrek and Dubin from 2010.[65] Thus, linear plots of logKb
versus logcs are found in a number of investigations.
[65] The
number of quantitative studies employing Equation (3),
however, is rather small given the obvious importance of
GAGs as biomaterials.[19, 155, 156] It is important to note that
electrostatic interactions with heparin are already used in
medical applications. Thus, protamine, which is a highly
cationic polypeptide, is used to neutralize an overdose of
heparin.[157] A detailed discussion of this application will be
given in Section 4.
Figure 3. Chemical structure of the monomer unit of heparin.
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2.6. Linear Synthetic Polyelectrolytes that Interact with Proteins
Less quantitative work has been carried out using ITC on
the interaction of synthetic linear polyelectrolytes with
proteins. Careful work by Dubin and co-workers, however,
has shown that charge–charge interactions are central for the
understanding of the complex formation between proteins
and various polyelectrolytes.[83,158–162] A first investigation of
the linear polyelectrolyte poly(allylamine hydrochloride)
with BSA by Ball et al.[163] using ITC demonstrated that the
driving force for complex formation is entropic. Equa-
tion (3a) was used repeatedly to model the interaction, and
in many cases a good linearity was found, at least at higher
ionic strength (see the discussion of this problem in
Ref. [109]) Recently, a careful investigation of this problem
was presented by Lounis et al. ,[164, 165] who demonstrated that
Equation (3a) provides an excellent description of experi-
mental data for the interaction of linear and dendrigraft
poly(lysine) with synthetic anionic polyelectrolytes.
We have recently analyzed the interaction of human
serum albumin (HSA) with short chains of poly(acrylic acid)
(PAA) in aqueous solution as a function of the ionic strength
and temperature.[50] The low molecular weight of PAA
prevented the formation of complex coacervates, and ITC
could be used for a fully quantitative analysis of DGb. Figure 4
shows that Equation (3) is valid for higher ionic strengths,
whereas low salt concentrations led to deviations, as discussed
above. The simplicity of this systems allowed us to perform
molecular dynamics (MD) simulations of this binding process.
Figure 4b displays a simulation snapshot of a complex
between HSA and poly(acrylic acid). The simulations suggest
that the linear polyelectrolyte is bound in the Sudlow II site,
which is to be expected from earlier studies of HSA.
Moreover, the number of released counterions could be
obtained from the simulations. This number can be compared
to the experimental result obtained through application of
Equation (3a) (Figure 4a). We found three counterions to be
released in the binding process from simulations as well as
from the experiment.[50] Thus, the good agreement between
theory and experiment corroborates the analysis of binding in
terms of Equation (3a).[50]
It is important to check whether a given protein is changed
upon interacting with a polyelectrolyte. In this case, a part of
the caloric signal would be due to a partial denaturation or
a refolding of the protein. For the case of DNA interacting
with various proteins, this problem has been investigated by
Privalov et al.[138] (see also the discussion in Ref. [11]) and by
Jen-Jacobson et al.[13] For the system HSA/PAA discussed
above, the resulting complexes have been analyzed by small-
angle neutron scattering (SANS).[166] No significant changes
in the overall structure of HSA could be detected by this
method. CD spectroscopy is an excellent tool to reveal
possible changes in the secondary structure of com-
plexes.[167–170] Thus, if HSA interacts with dendrimers having
partially hydrophobic moieties, there is a significant loss of a-
helices.[170] Tests on the secondary structure of a protein in
a complex with a given polyelectrolyte are therefore man-
datory.
From the results obtained for a large number of natural
and synthetic systems, one can state that the analysis of DGb in
terms of Equation (3) has led to a semiquantitative under-
standing of the interaction of polyelectrolytes with proteins.
The effect of counterion release can be separated from the
other factors by use of Equation (3a), which provides the first
step towards the quantitative understanding of DGb. ITC
measurements have turned out to be central for these studies
and MD simulations will allow us to acquire a molecular
understanding of the thermodynamic data.
2.7. Biotechnological and Medical Applications of Linear
Synthetic Polyelectrolytes
An important application of charge–charge interaction is
gene delivery by nonviral vectors.[22, 23, 171–173] Here, cationic
polyelectrolytes are used to compact DNA and RNA by
formation of so-called polyplexes.[20] The micelles and aggre-
gates formed by this interaction may then form more complex
supramolecular structures.[174] Polyethyleneimine (PEI) has
been the cationic polyelectrolyte of choice.[175, 176] Concerns
about the inherent toxicity of PEI has led to an enormous
number of studies that have tried to improve gene delivery by
Figure 4. Interaction of linear synthetic polyelectrolytes with proteins.
a) The binding constant of poly(acrylic acid) to human serum albumin
(HSA) is plotted against the log of the salt concentration. At high salt
concentrations, there is a linear relationship, the slope of which gives
the number of released counterions according to Equation (3). Devia-
tions at low salt concentrations point to a residual Debye–Hckel
repulsion between the protein and the polyelectrolyte. b) MD simula-
tion of the interaction of the interaction of HSA with poly(acrylic acid).
The polyelectrolyte is bound to the Sudlow II site of HSA.[50]
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designed block copolymers, which has recently been review
by Kataoka and co-workers[25] and by Reineke and co-
workers.[177] Charged dendrimers have also been used for this
purpose.[178] An interesting application is the delivery of
proteins through a suitable packaging by block copolymers
with charged blocks. Here, we only cite recent work on block
copolymers that deliver the CRISPR/Cas9 system[179] and the
nanoformulation of the brain-derived neurotrophic factor
(BDNF) by a block copolymer containing a poly(glutamic
acid) block.[60] In the latter case, cationic patches on the
BDNF interact electrostatically with the negatively charged
block, and the resulting supramolecular structures then lead
to a better delivery of the BDNF.
It is interesting to note that linear polyelectrolytes may act
as synthetic chaperones thus, guiding proteins to adopt the
correct tertiary structure. This was shown by Semenyuk et al.
in a series of careful studies.[180–182] The complexes of the
proteins with polyelectrolytes such as polystyrene sulfonic
acid also stabilized the structure of the proteins against
aggregation in a very efficient manner. Furthermore, the
complexes were stable at temperatures where the free protein
would be denatured. This complexation of proteins with
linear polyelectrolytes hence holds the promise for further
biotechnological applications.
A totally different problem of medical relevance arises
when considering the interaction of short-chain polyelectro-
lytes and small charged molecules such as phenylacetic acid
with HSA. These substances adhere strongly to HSA and are,
therefore, difficult to remove by a conventional dialysis.
Patients with chronic kidney disease have high concentrations
of such uremic toxins, which may lead to a higher cardiovas-
cular morbidity.[166, 183, 184] ITC is a central tool for analyzing
the interaction of such toxins with HSA.[166] Here, short
polyelectrolytes may serve as models for the so-called middle
molecules that present uremic toxins stemming from
degraded proteins (cf. Ref. [166]). The interaction with HSA
is mainly depends on counterion release, as shown above.[50]
Small toxins such as phenylacetic acid or indoxyl sulfate,
however, interact mainly with the hydrophobic sites of HSA
and exhibit a rather high binding constant.[166] Removal of
uremic toxins is, hence, a central task of clinical nephrology
and an improved thermodynamic understanding of their
interaction with HSA is absolutely necessary.
3. Charged Networks, Dendritic and Hyperbranched
Polyelectrolytes, and Polyelectrolyte Brushes
3.1. Dendritic and Hyperbranched Polyelectrolytes
The previous section has demonstrated that the interaction
of proteins with linear polyelectrolytes can be largely understood
and modeled. In a next step, we consider more complicated
structures and start with branched and dendritic polyelectrolytes.
Highly charged dendrimers have been the subject of intense
research since the first pioneering theoretical study by Welch
and Muthukumar[186] in 1998. Charged dendrimers have been
studied for gene transfection for a long time,[172, 178, 187–191] and
discussed for drug delivery in general.[192–194]
We have recently investigated charged dendritic polygly-
cerols. Figure 5 gives a survey of these systems and the main
results achieved so far. Figure 5a displays the chemical
structure of the polyanionic dendritic polyglycerol sulfate
(dPGS). The scaffold consists of the highly hydrophilic
polyglycerol, on to which sulfate groups are appended.
These systems based on hyperbranched polyglycerol were
made for the first time in 2004[185] and used for various
medical purposes.[34]
In a first step, for a better understanding of the interaction
of dPGS with proteins and more complicated biological
systems (see Figure 2), we have studied the spatial structure
of these dendrimers. First, MD simulations were used to
explore the interaction of the highly charged systems with
their counterions.[51] Figure 5b displays a typical simulation
snapshot of a dPGS dendrimer of the 2nd generation. The
segments of the scaffold and the end groups were modeled in
a coarse-grained fashion. It is clear that these systems present
rather dense structures, where the charged groups are located
mainly at the outside. Simulation can serve to define an
approximate surface of the dendritic structure that may be
compared with measured hydrodynamic radii.[51] The counter-
ions are highly correlated to the macroion and form a dense
layer on the surface of the dendrimer. Hence, a surface
concentration cci may be defined in the same way as already
discussed in conjunction with linear polyelectrolytes [see the
discussion of Equation (1)]. This surface concentration is on
the order of 1m for a dPGS of second generation and rises
considerably for higher generations.
It is important to understand that correlation of the
counterions with the highly charged dendrimer proceed on
a mesoscopic level, in which molecular details play a minor
role. Coarse-grained simulations may hence lead to a better
understanding of the counterion release mechanism, but
cannot reveal details of interactions related to, for example,
hydrogen bonding. However, MD simulations can be directly
compared to the hydrodynamic radius, and the effective
charge determined experimentally.[51] These data agree with
the simulations within the limits of error. In particular, the
effective surface charge levels off with increasing number of
generations, while the bare charge increases exponentially.
Thus, these systems exhibit the charge renormalization
expected for highly charged spherical macroions.[51] This
charge renormalization must be kept in mind when compar-
ing the interaction of charged dendrimers of different
generations with proteins. Evidently, these systems are
expected to interact with proteins through counterion release
in the same way as already discussed for the linear systems
above. Furthermore, a salt concentration of 1m will lead to
a vanishing contribution of the counterion release [see
Eq. (6)] and provide a good reference state. The results of
these coarse-grained simulations have been checked and fully
corroborated by atomistic simulations with explicit water.[195]
In a second step, MD simulations turned out to be highly
revealing when studying the interaction of dPGS with
proteins.[45, 53] Figure 5c displays the ITC diagrams for the
interaction of a second-generation dPGS with lysozyme in
aqueous solution. A parameter of the different curves is the
ionic strength in these solutions, which ranges from 10 mm to
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a physiological concentration of 150 mm. The weakening of
the interaction with increasing ionic strength is directly
apparent, and the inset of Figure 5c shows that the logarithm
of the binding constant scales linearly with the salt concen-
tration cs in solution, as predicted by Equation (6). The slope
of these lines leads directly to the number of released
counterions (three), in good approximation to that already
discussed in conjunction with Equation (6). Moreover, the
free energy of binding DGb is nearly independent of temper-
ature, which is followed by a strong compensation of the
enthalpy and the entropy of binding. This particular point will
be discussed further in Section 3.5.
MD simulations now lead to data that can be directly
compared to experiments: Figure 5d displays a typical snap-
shot of a complex in which four lysozyme molecules are
bound to a third-generation PGS. First of all, the interaction
of the protein with a dPGS molecule is quantitatively
obtained by steered Langevin simulations: Here the centers
of gravity of the dPGS and the protein are kept at a fixed
distance and the force between the two molecules is averaged.
By integration over the distance, we obtain a potential of the
mean force, the maximum of which is the free energy of
binding DGb. Moreover, the number of released counterions
and the average number of bound proteins can directly be
obtained from these simulations and compared to experi-
ments. A comparison with experimental data showed an
excellent agreement.[45, 50, 53] The number of released counter-
ions derived from the simulations compare very well with the
experimental data (cf. the discussion of Figure 5c). Moreover,
it was demonstrated that the free energies derived from
simulations can be directly compared to experimental data.
Here again, good agreement is found.[45] Hence, MD simu-
lations provide an excellent tool for the quantitative under-
standing of the interaction of polyelectrolytes with proteins.
The same combination of ITC and MD simulations was
recently applied to complexes formed between second-
generation dPGS and HSA.[53] The same features as discussed
for the dPGS/lysozyme system are found here as well: A well-
defined 1:1 complex is formed and counterion release is found
to be the main driving force. Again, a strong EEC is found by
ITC measurements as a function of temperature. The
experimental binding constant again agrees with the simu-
lated one within the limits of error. The CD spectra of the
complex measured up to 310 K showed no significant change
Figure 5. Sulfated dendritic polyglycerol (dPGS) and its interaction with proteins. a) Chemical structure of dPGS. The scaffold consists of a highly
hydrophilic dendritic or hyperbranched structure, with each end group carrying a sulfate group.[185] b) Snapshot of the coarse-grained structure of
a second-generation dPGS. Red beads mark the terminal sulfate groups of the dendritic structure, and yellow beads mark its scaffold. The
counterions are displayed as green beads.[51] c) Interaction of a second-generation dPGS with lysozyme measured by ITC at different ionic
strengths. The incremental heat per injection is plotted against the molar ratio of lysozyme to dPGS in aqueous solution. The inset displays the
log of the resulting binding constant as a function of the log of the salt concentration according to Equation (3).[45] d) Coarse-grained MD
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when compared to the spectra recorded at room temperature.
This finding is in contrast to complexes formed by a PAMAM
dendrimer with HAS, where a major reduction of the a-helix
content was found because of partial unfolding.[170]
The MD simulations of dPGS interacting with pro-
teins[45, 52, 53] were carried out using only implicit water, that
is, all simulations have assumed water to be a structureless
medium with a given dielectric constant. Here the question
arises in what way water is involved in the process of binding.
This problem has recently been elucidated further by
reconsidering the measured binding constant of the dPGS/
lysozyme[52] system in terms of Equations (5)–(7).[54] Fig-
ure 6a shows a typical plot of the measured binding constant
as a function of the salt concentration cs according to
Equation (3a). The strict linearity of this plot allows us to
determine the number of released counterions with good
accuracy. Moreover, the binding constant Kb(1m) could be
extrapolated with equal precision and used for the breakdown
of the measured data, according to Equation (5), into to a part
(DGci) solely due to counterion release and a residual part
(DGres) due to specific interactions, such as salt bridges and
hydrogen bonding. At the same time, the enthalpy of binding
was largely balanced by an entropic term of comparable
magnitude. Figure 6b displays a plot of the enthalpy of
binding versus the residual entropy of binding DSres multiplied
by T [see the discussion of Eq. (7)]. All data collapse on
a single master curve that shows that the breakdown of the
free energies of binding according to Equation (5) provides
an excellent approximation for the data. This master curve is
given by Equation (8).
DHb ¼ 21:3þ 1:017  TDSres ð8Þ
The intercept of 21.3 kJmol1 is, hence, the average
value of DGres for the present system, and the slope very near
to unity shows that there is a nearly full compensation of the
enthalpy by entropy.
It is interesting to note that this master curve obtained for
the dPGS/lysozyme[52] system shown in Figure 6b) virtually
coincides with the master curve found by Dragan et al. for
some 30 systems in which DNA interacts with various
proteins (dashed line in Figure 6b). The slope of this master
curve is slightly higher than 1 (1.09 vs. 1.017 for the dPGS/
lysozyme system) and DGres is slightly smaller. Despite these
small differences, both investigations agree that the binding of
proteins to DNA leads to a marked EEC with a non-zero
value of DGres. Dragan et al.
[11] explained the marked EEC by
the uptake or release of water during binding. Our findings[54]
underscore this idea and demonstrate, in addition, that the
binding of dPGS to proteins may be directly compared and
modeled as the binding of DNA to various proteins.
3.2. Sulfated Polyglycerol as an Anti-inflammatory Drug
As already mentioned in the Introduction, dPGS has
a strong anti-inflammatory effect.[34, 36, 196] Figure 7 shows the
mode of action of dPGS: The recruitment of leukocytes to the
sites of inflammation is an important step in the pathogenesis
of acute and inflammatory diseases, which include hyper-
sensitivity reactions and autoimmune diseases. This process is
orchestrated by gradients of cytokines and chemokines and by
distinct expression and activation of several family members
of adhesion molecules, including selectins and integrins.
Dernedde et al. demonstrated that dPGS binds to the
positively charged amino acid residues (arginines) close to
the carbohydrate binding pocket of L-and P-selectin with high
affinity in the nanomolar range; no binding takes place with
E-selectin due to the absence of basic residues.[36] As
discussed above, these findings were recently directly
proven by MD simulation of the interaction of these selectins:
Figure 6. Thermodynamic analysis of the binding of lysozyme to
a second-generation dPGS.[54] Top: A plot of logKb versus log cs as
suggested by Equations (4) and (6). There is a perfectly linear relation
in this double-logarithmic plot, in which the slope gives the number of
released counterions, as discussed in conjunction with Equation (3a).
The linear relationship is used to extrapolate the binding constant DGb
at a salt concentration of 1m. Kb(1m) is related to DGres, the residual
of the Gibbs free energy of binding according to Equation (5,) and
reflects all contributions to DGb not related to counterion release.
Bottom: Enthalpy–entropy compensation for the data obtained on the
system dPGS-G2/lysozyme. The enthalpy DHb is plotted against
TDSres = TDSbTDSci according to Equation (7). The solid line denotes
the fit by Equation (8). The dashed line shows the master curve
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Counterion release was found to be the main driving force for
binding, and the experimental binding constant of a third-
generation dPGS with L-selectin[78] could be reproduced by
the simulation in a nearby quantitative fashion.[45]
It is important to note that ion-specific effects may play an
important role as well. Thus, Weinhart et al. analyzed the
interaction of several polyglycerol-based anions with L-
selectin.[197] The strength of interaction increased in the
order carboxylate (no inhibition)< phosphate< phospho-
nate sulfonate< bisphosphonate< sulfate. Hence, the elec-
trostatic effect alone cannot be solely responsible for the
strength of binding. Furthermore, Paulus et al. studied the
effect of dPGS-branching on the inhibition of inflammatory
processes.[191] It was found that a dPGS with a degree of
branching of 60% had a higher binding strength than
a sulfated, perfect dendrimer characterized by a degree of
branching of 100 %. More recently, biodegradable dPGS was
shown to exhibit promising features for anti-inflammatory
applications, thus replacing heparin.[196] All the results
obtained so far clearly reveal charge–charge interactions to
be the major driving force for binding.
In the meantime, several inflammation and tumor-rele-
vant proteins were identified as nanomolar binders for dPGS,
such as interleukin-1 (IL-1), L-selectin, P-selectin, interleu-
kin-6 (IL-6),[198] lectin-type oxidized low-density lipoprotein
receptor 1 (LOX-1),[199] and the complement factors C1q and
C5a.[200] The binding of dPGS is rather unspecific and does not
necessarily depend on a unique protein structure. This is in
contrast to species-specific inhibitors that target ligand–
receptor interactions with peptides, proteins, or antibodies.
Thus, targeting by
dPGS is much less sen-
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a number of soluble
blood proteins that
are activated through
a proteolytic cascade mechanism. Inhibition at distinct
checkpoints paralyze the complement activation and are of
importance in several pathologies characterized by dysregu-
lated excessive activation, with sepsis being the most prom-
inent disease.[202,203] Recently, Silberreis et al. identified that
dPGS targets the three different pathways of the complement
cascade and that charge–charge interaction plays an impor-
tant role to balance the activation (Figure 8).[200] It was shown
that dPGS binding to the complement factors C3 and C5
inhibits further processing and subsequent release of the
anaphylatoxins C3a and C5a. In addition, charge-dependent
sequestration limits the anaphylatoxin function. Highly
charged polyelectrolytes such as heparin and heparan sulfate
were shown to act similarly,[204] but by far not as effective as
the synthetic polymer dPGS that binds the anaphylatoxin C3a
with low micromolar affinity and C5a with nanomolar
affinity.[200] Thus, dPGS may be a promising candidate for
a drug that counteracts an overshooting complement activa-
tion in sepsis and other diseases such as rheumatoid
arthritis.[205–207]
3.4. Interaction of dPGS with Cellular Systems
The effect of dPGS on neural cells was also investigated in
models of endotoxemia caused by lipopolysaccharide (LPS)
in primary neural cultures and in animals.[198] Figure 9 shows
the main findings in a schematic fashion: dPGS can reduce the
negative impact of cytokines on neural brain cells through
attenuation of the hyperactivity of microglia and lipocalin-2
Figure 7. The anti-inflammatory effect of dPGS. As shown by Dernedde et al.,[36] dPGS inhibits an overwhelming
inflammatory response and reduces the extravasation of leukocytes. dPGS targets the adhesion molecules L- and
P-selectin, while no binding to E-selectin is observed. The same finding was made in our recent study by MD
simulations.[45] Thus, dPGS acts by preventing leukocyte extravasation through the binding of the selectins.
Moreover, binding to complement factors C3 and C5 inhibits the formation of the proinflammatory anaphylatoxins.
Here, the reduction of the C5a level decreases further leukocyte activation and recruitment. As a result, the
adhesion cascade is balanced and contributes to initiate the healing process.[196]
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release from astrocytes. Enhanced microglia activation
caused astrocyte activation, and dPGS was a powerful
modulator of the cross-talk between the microglia and
astrocytes. dPGS directly bound to IL6, thereby preventing
the binding of cytokine to its receptors and reduced the
propagation of neuroinflammation. dPGS was internalized
both by microglia and astrocytes in a concentration- and time-
dependent manner.
Aside from strong neuroglia activation by LPS, Ab42
oligomers can also activate neuroglia but to a lesser
extent.[40] The mechanism of the dPGS action involved
a direct binding of the Aß42 oligomers to dPGS, thus
interfering with the formation of Ab fibrils.[40] The treatment
with dPGS prevents the deleterious effects of oligomeric Ab
on dendritic spines at the excitatory synapses in the hippo-
campus and normalizes the neuroglia activity in this brain
structure (Figure 9). Taken together, these studies suggest
that dPGS is a valid candidate for therapeutic interventions in
neurodegenerative disorders implicating neuroinflammation
of the central nervous system.
Summing up the previous work related to dPGS and its
application to various systems and medical problems, it
becomes evident that the marked localization of the counter-
ions on the surface of these dendritic structures provides the
key for the understanding of the results: MD simulations
together with experiments[51] demonstrate that the high
charge density on the surface leads to a surface concentration
of counterions of the order of 1m [see the discussion of
Equation (3)]. Electrostatic interaction with proteins and
more complicated systems will release a part of these surface-
bound ions into the bulk solution with a reduced ion
concentration. In cells, this concentration is 150 mm, whereas
the extracellular matrix is characterized by even lower salt
concentrations. Binding will be brought about by entropic
forces that work even under physiological salt concentrations.
Evidently, this counterion release force is only one part of the
free energy, other factors, such as the release of water
molecules and hydrogen bonding, will come into play as well.
3.5. Polyelectrolyte Brushes
If long linear polyelectrolyte chains are appended to
planar or curved surfaces, a polyelectrolyte brush
Figure 8. Complement pathway: dPGS interferes with the three path-
ways of complement activation and reduces formation of the mem-
brane attack complex (MAC), which is a pore that is inserted into the
cytoplasmic membrane and thereby leads to cell death. Reduced
activity of the C3 and C5 convertase results in IC50 values of 60 nm
(lectin pathway), 300 nm (classical pathway), and 900 nm (alternative
pathway).[200]
Figure 9. Modulatory effects of dPGS in neuroinflammation caused by Aß oligomers. a) Exposure of microglia to Ab oligomers causes the
activation of microglia and loss of dendritic spines in the hippocampal excitatory neurons. Hyperactive microglia activate astrocytes and these
glial cells (reactive astrocytes) produce excessive amounts of lipocalin 2 (LCN2). LCN2 in combination with cytokines released from hyperactive
microglia contribute to the impairment of synaptic functions. b) dPGS attenuates microglia hyperactivity, binds to Ab42 and normalizes the
number and function of dendritic spines.[40]
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results.[110, 209–212] The brush limited is reached when the
average distance between the grafted chains on the surface
is smaller than their dimensions in solution.[209] The inter-
action of these polyelectrolyte brushes with proteins has been
the subject of a large number of studies, which have been
reviewed recently.[109] Hence, a brief discussion of this
problem will suffice here. Figure 10 displays schematically
the adsorption of proteins on spherical polyelectrolyte
brushes. For a low ionic strength in solution, 95–98 % of the
counterions are confined within the brush layer.[110, 213, 214] This
confinement will lead to a high osmotic pressure within the
brush layer and a concomitantly strong stretching of the
polyelectrolyte chains.[214] The uptake of proteins will lead to
a partial release of these counterions, which is the main
driving force for adsorption.[111, 215] At high ionic strength, on
the other hand, the limit of a salted brush is attained.[211, 213,214]
at this limit, proteins can hardly adsorb on the brush layer.
Moreover, adsorbed proteins will be released when
going from a low ionic to a high ionic strength.[216, 217] The
interaction of proteins with such a dense polyelectrolyte layer
can, hence, be understood in terms of the counterion release
force discussed above in Section 2.1. FTIR spectroscopic
studies revealed that there is hardly any change in the
secondary structure of the adsorbed proteins.[218, 219] The same
conclusion could be drawn from the activity of adsorbed
enzymes[220, 221] and from spectroscopic studies of the green
Figure 10. Uptake of proteins by a spherical polyelectrolyte brush (SPB).[208] Top: The polyelectrolyte brushes consist of a solid polystyrene core
(gray sphere) with a radius Rh,core between 50 and 100 nm. Onto its surface are grafted long chains of polyelectrolytes, for example, poly(acrylic
acid). Red spheres on the PAA chains represent the negative charge of the acidic residues, while blue spheres represent the positive counterions.
Nearly all of the counterions of the brushes are confined within the brush layer (osmotic brush). The protein molecules are represented by green
spheres. Their uptake will lead to the release of a concomitant number of counterions. Adsorption of proteins by polyelectrolyte brushes is hence
mainly entropy-driven.[109, 208] Bottom: a) The Gibbs free energy of binding DGb of HSA to a spherical polyelectrolyte brush carrying long chains of
poly(acrylic acid) (black squares) compared to the results for HSA binding to dPGS and of HSA interacting with linear chains of poly(acrylic acid).
In all cases, the ITC-determined DGb exhibits only a weak dependence on temperature, which is followed by a strong enthalpy–entropy
compensation (EEC) shown in (b) for HSA interacting with a SPB: Both DHb as well as TDSb vary strongly with temperature, whereas DGc stays
nearly constant because of the EEC.[208]
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fluorescent protein adsorbed on a spherical polyelectrolyte
brush.[217]
It is interesting to note that the adsorption of proteins on
spherical polyelectrolytes is accompanied by a marked
enthalpy–entropy compensation, exactly in the way discussed
for the dPGS/lysozyme system (see the discussion of Figures 5
and of 10 b,c). A recent study[208] of the adsorption of human
serum albumin on a spherical polyelectrolyte brush by ITC
has revealed that the free energy of binding depends very
little on the temperature, while the enthalpy and the entropy
of adsorption vary linearly with temperature (Figure 10 c).[208]
Figure 10 b,c suggests that the strong enthalpy–entropy com-
pensation is a general feature that always occurs when
polyelectrolytes interact with proteins—from the complexes
of DNA with proteins[11, 49,91] to the binding of proteins to
synthetic polyelectrolytes.[54, 109,208] A fully quantitative theory
of this effect, however, is still lacking.
3.6. Charged Networks
Networks bearing charges have been a classical subject of
polymer science and the first quantitative theory dates back to
the classical paper of Michaeli and Katchalski from 1955.[222]
More recently, charged networks have been the subject of
a series of comprehensive theoretical studies by Košovan,
Holm, and co-workers.[76,223–225] It is fair to state that we now
have acquired a very good physical modeling of these systems
that helps us to understand their interaction with proteins.
Figure 11 shows the main feature of charged networks
exemplified for charged core–shell particles:[73, 74] The coun-
terions are fully confined within the network and the total
number of co- and counterions within the network is
determined through the Donnan equilibrium. The Donnan
potential determines the leading term for the interaction of
charged entities such as proteins with the network. The
decisive parameter for protein uptake is the difference in the
ionic strength inside and outside the network and the overall
charge of the proteins.[74]
There is a large number of experimental studies related to
the uptake of proteins by charged networks, which started
with a series of investigations by Kabanov, Zezin et al.[55,226]
Later studies include the work of Cohen-Stuart and co-
workers.[227] A more detailed discussion of these investiga-
tions is beyond the scope of the present Review. Here we only
mention the studies by Yigit et al. ,[73, 74] who investigated the
uptake of various proteins by charged core–shell microgels
and compared the findings to their theoretical model. In
particular, Oberle et al.[74] were able to show that this model
can even predict the results of the competitive adsorption of
two different proteins, thus demonstrating the power of
a purely analytical model. Moreover, the difference in the
free energy between the free and the adsorbed state of
a protein can be used in Dynamic Density Functional Theory
(DDFT) to model the kinetics of protein uptake into a net-
work.[75] DDFT is also capable of describing non-monotonous
effects in competitive adsorption[228] (“Vroman effect”; cf. the
discussion in Ref. [212]).
In a series of papers, Werner and co-workers develop
biocompatible highly charged hydrogels that can be used to
adsorb and hence act as medical aids.[27, 31, 56,71, 229] Glycosami-
noglycan (GAG) based hydrogels with a varied GAG content
and GAG sulfation pattern were prepared and applied to
sequester cytokines. Cytokines are small proteins with various
isoelectric points. Hydrogels containing GAGs with different
sulfation patterns have been shown to adsorb cytokines,
chemokines, and growth factors.[31, 56] Thus, networks contain-
ing defined GAG sequences can be employed, for example,
for healing of chronically inflamed wounds by sequestering
various cytokines. A review of this application and others has
recently been provided by Werner and co-workers.[31]
3.7. Virus Inhibition by Nanogels
As mentioned in Section 2.5, heparan sulfate (HS)
moieties are located in the extracellular matrix and the
glycocalyx. They are involved in the infection of many viruses
through interaction with secondary receptors.[37, 69, 79,80, 145] In
general, viruses attach to and ultimately enter cells using
multivalent interactions of viral ligands with receptors
localized on the cell surface. Hence, nanoparticles of suitable
size and that are highly charged can be used as multivalent
Figure 11. Modeling the competitive adsorption of proteins onto
charged networks as exemplified by charged core–shell microgels.[73, 74]
The shell consists of a charged network built up of hydrophilic chains.
The network contains negatively charged monomer units, which lead
to a charge density cg. The concentration of the counterions and the
co-ions within the network are regulated by the Donnan potential. The
proteins are modeled by charged spheres with charge numbers z1 and
z2, respectively, whereas the overall radii are given by R1 and R2,
respectively. The uptake of proteins is governed by the interaction of
the charged proteins with the Donnan potential of the network.[73] The
model can consider the competitive adsorption of several proteins
onto the network.[74] Here, two different proteins with effective charges
z1 and z2 undergo competitive adsorption to the charged core–shell
particle. The model leads to a fully quantitative understanding of the
experimental results with four different proteins.[74]
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receptors that compete with HS and thus block the docking of
viruses on the cell surface.[37] Sulfated nanogels with a size of
100–200 nm to match the virus size were synthesized and
tested as antiviral agents. Flexibility of the cores turned out to
be important because it resulted in a more effective shielding
of the surface of the virus. Dey et al.[37] demonstrated that, for
example, HSV-1 viruses are blocked by charge–charge
interactions: The positively charged glycoproteins on the
virus surface normally adhere to the negatively charged HS.
Highly charged dPGS microgels can suppress this interaction
by adhering to the virus and thus prevent the uptake of the
virus by the cell. Thus, charge–charge interactions, most
probably by counterion release, seems to be central for
a clearer understanding of virus uptake and inhibition.
4. Complex Polyelectrolyte Architectures
In the last section of this Review, we now turn to systems
with higher complexity. Here we deal with rather large
polymeric structures that have been generated through the
formation of covalent bonds or by self-assembly, for example,
micelles. These systems have been designed for special
purposes, such as drug delivery, and must match a number
of requirements: Low toxicity should be combined with high
efficiency for targeting, for example, tumor cells. The
polymeric scaffold with a size of 10–100 nm should be
degradable for full clearance afterwards. The synthesis and
analysis of complex architectures fulfilling these conditions
certainly presents a great challenge, and the number of
systems near to clinical use is still small. Here we choose two
major problems in which polymeric systems have been
applied successfully so far, namely drug delivery and anti-
coagulant reversal.
4.1. Drug Delivery
Micelles based on block copolymers with a charged block
play a central role in this field. If the charged segments are
characterized by a charge parameter x> 1, counterion release
will again be a major driving force for self-assembly.[88, 230,231]
Polymersomes present another example for complex poly-
meric carrier systems.[232] Much of this work has been
reviewed recently by Kataoka and co-workers,[25] and so the
present discussion of carrier systems will be focused more on
recent studies using dPGS micelles.
Ideal polymeric drug carriers should, of course, fulfil two
requirements: The micelles should be nontoxic and not
interact with blood proteins. A strong adsorption of various
blood proteins may lead to prompt immune reactions and
opsonization (cf. the discussion in Refs. [233–235]). This
problem has been addressed in many systems by a dense
coating of poly(ethylene glycol) chains. Moreover, the
micelles should carry their payload, for example, an anti-
cancer drug, directly to the cancerous tissue in a highly
specific manner. This requires concepts for targeting micelles
and presents an important problem for present research (cf.
the discussion of this point by Cabral et al.[25]).
4.2. Micelles for Tumor Targeting
Dendritic dPGS-based polymer micelle and the dPGS
dendritic copolymer are highly potent candidates for the
targeted delivery of poorly water-soluble drugs. The extra-
ordinary potential of such dPGS copolymer micelle formu-
lations was first demonstrated by Zhong et al.,[38] who used
a disulfide-bridged, cleavable dPGS-SS-PCL copolymer
micelle (Figure 12) for the encapsulation of poorly water-
soluble dyes. This study provided the first demonstration of
tumor-targeted delivery and drug release for an intrinsic
tumor-affine polymer.[38] To prove the applicability of dPGS
copolymer micelle formulations of doxorubicin in vivo,
Zhong et al. first investigated the elimination of doxorubicin
from the blood in mice. Both cleavable and no-cleavable
micellar formulations delayed the elimination of doxorubicin
from the blood (Figure 12 b). A factor of 10 increase in the
bioavailability after a single parental application of doxo-
rubicin was shown.
Further proof of concept was provided by the treatment of
established human mammary MCF-7 xenografts in nude
mice. For this purpose, the hydrophobic anticancer drug
doxorubicin was encapsulated within both the cleavable and
noncleavable dPGS PCL copolymer micelle. The growth
inhibition of human MCF-7 mammary carcinoma cells
in vitro was demonstrated with both formulations. We dem-
onstrated that both cleavable and noncleavable dPGS co-
polymer micellar formulations of doxorubicin may increase
the survival of tumor-bearing mice compared to vehicle- or
doxorubicin-treated controls. However, stable long-term
survival in 100 % of implanted tumors was only achieved by
repeated treatment with the doxorubicin-loaded cleavable
dPGS-SS-PCL micelles, which can release more antitumor
drug specifically inside the cells of the tumor tissue.
4.3. Polycation-Based Therapeutics for Polyanion Neutralization
in Blood
Heparin-based anticoagulant drugs (unfractionated hep-
arin (UFH), low molecular weight heparins (LMWHs), and
fondaparinux) are widely prescribed for prophylaxis and the
treatment of thromboembolic disorders, as well as in sur-
geries.[236, 237] Despite its widespread use in clinics, a major
limitation of this class of drug is a side effect of bleeding,
which necessitates the need for antidotes which can neutralize
their anticoagulant activity.[42, 238] To date, protamine is the
only clinically approved antidote for UFH; however, it is not
effective against all heparins.[42, 238] Protamine is a highly
cationic polypeptide that interacts electrostatically with
negatively charged heparins to form stable complexes,
thereby providing antidote activity.[157] Its cationic charge
density and binding strength is not sufficient to generate
a stable complex with LMWH or fondaparinux because of
their low molecular weight and low degree of sulfonation (see
Section 2).
To overcome these deficiencies, the Kizhakkedathu group
recently developed an UHRA, a synthetic nontoxic macro-
molecular heparin antidote capable of neutralizing all clin-
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ically available heparin-based anticoagulants.[41, 43,239–242] Fig-
ure 13a shows the chemical structure of the UHRA and its
way of interacting with the antithrombin/heparin complex
(Figure 13 b). The UHRA consists of a core of HPG and
tertiary amine based heparin binding groups that acquire
cationic charges at a physiological pH value. This core is
protected by a shell of methoxypolyethylene glycol (mPEG)
chains (brush layer). Unlike the naked cationic charges in
protamine, the shielded dense cationic charge within the
UHRA prevents its ionic interaction with endogenous anionic
macromolecules in blood such as proteins (e.g. fibrinogen,
coagulation factors) and cells (platelets, red blood cells). The
mPEG brush layer offers sufficient entropic penalty to the
incoming polyanions as a result of brush compression; thus,
only those highly charged polyanions such as heparins can
overcome such a barrier, thereby providing selectivity to
UHRA.[41] Thus, charge–charge interactions and probably
counterion release play a major role in these processes.
5. Conclusion
The survey of investigations on natural and synthetic
polyelectrolytes demonstrates that their interaction with
proteins is largely dominated by charge–charge interactions.
Section 2 shows that this interaction can be described by
counterion release embodied in Equation (3). A similarly
clear picture emerges from the studies done on dendritic
polyelectrolytes, brushes, and networks
summarized in Section 3. Specifically,
systems based on dendritic polyglycerol
sulfate (dPGS) are already applied in
animal models for medical purposes, for
example as anti-inflammatory drugs,
and the better understanding of the
interaction of dPGS with proteins now
achieved will certainly pave the way for
many further applications. The situation
is less clear for the more complex
polyelectrolyte architectures discussed
in Section 4. However, all the results
obtained so far demonstrate the impor-
tance of charge–charge interactions,
most probably related to counterion
release. Moreover, all the investigations
discussed here clearly reveal the impor-
tance of temperature as a decisive var-
iable: In all the cases studied so far,
a strong enthalpy–entropy compensa-
tion is observed. Further work is needed
on this phenomenon and to explore its
importance in living systems. The entire
survey, however, clearly demonstrates
that a much better understanding of
charge–charge interactions is the key for
the design of drugs based on polyelec-
trolytes.
At this point, we now suggest further
work along the following lines: For
a given architecture of a polyelectrolyte, two parameters are
decisive: 1) ionic strength and 2) temperature. Hence, a mean-
ingful study of the interaction of a polyelectrolyte system
must always vary these two parameters. In particular, the
investigation of potential drugs based on polyelectrolytes
must always include experiments at 37 8C, which may lead to
distinctly different results to the ones conducted at room
temperature. Calorimetric studies carried out as a function of
the salt concentration and temperature should be used to
reveal and to design the strength and specificity of the
interaction. Finally, the huge potential of MD simulations
must be explored further. Here, a combination of simulations
with studies on single molecules may be a new and very
interesting avenue.[243–246] Taken together, synthetic polyelec-
trolytes and systems derived therefrom are certainly highly
promising candidates for the development of drugs.
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Understanding the Interaction of
Polyelectrolyte Architectures with
Proteins and Biosystems
Polyelectrolytes such as DNA or heparin
are long linear or branched macromole-
cules onto which charges are appended.
The counterions neutralizing these
charges can dissociate in water and this
will largely determine the interaction of
such polyelectrolytes with biomolecules,
particularly with proteins. This Review
discusses studies on the interaction of
proteins with polyelectrolytes and how
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